Zinger Key Points
- All four cannabis stocks rose on robust quarterly earnings.
- Companies emphasize cost controls and expansion.
- Industry eyes regulatory shifts for future catalysts.
- Our government trade tracker caught Pelosi’s 169% AI winner. Discover how to track all 535 Congress member stock trades today.
Stocks in the cannabis sector notched notable gains on Thursday, according to Benzinga Pro data, with Cronos Group CRON up 3.82%, Verano Holdings VRNOF up 1.11%, Trulieve TCNNF up 3.37% and Green Thumb Industries GTBIF up 2.08%, following their respective earnings reports. Below is a closer look at each company's recently released results.
Cronos Group
Cronos reported fourth-quarter revenue of $30.3 million, marking a 26.7% increase year-over-year, driven largely by higher cannabis flower and extract sales in Canada and select international markets.
The company highlighted growth in the Canadian edibles segment, particularly with its SOURZ by Spinach brand, which continues to perform well.
Cronos also noted cost-optimization initiatives and a significant improvement in gross margin—rising from 8% to 36% in Q4, reflecting increased operational efficiency. Additionally, the company reported net income of $43.9 million in the fourth quarter, largely driven by a one-time gain rather than core operational performance. Management pointed to ongoing production and distribution enhancements as key to supporting long-term profitability.
Verano Holdings
Verano posted quarterly revenue of $218 million, reflecting an 8% decline year-over-year compared to $237 million in Q4 2023. Despite this, management noted that new dispensary openings helped offset price compression in certain markets.
Executives emphasized the company's focus on adult-use market expansion, particularly in Ohio, Maryland and New Jersey, while maintaining a disciplined capital expenditure plan for 2025.
For 2025, Verano plans a more disciplined capital expenditure program, with executives expecting pricing pressure to persist but remain manageable across core markets.
Trulieve
Trulieve's fourth-quarter revenue came in at $301 million, surpassing analyst expectations. The company also posted adjusted earnings per share of $0.02, benefiting from retail strength in Florida, where it maintains a dominant medical cannabis market position.
CEO Kim Rivers described Trulieve as "an industry leader with a differentiated strategy", highlighting a dispensary count of 229 nationwide and record cash flow from operations.
For 2025, the company plans targeted store renovations in Minnesota and Ohio and intends to expand automation initiatives to drive efficiency.
Green Thumb Industries
Green Thumb Industries posted $294 million in revenue for the fourth quarter, reflecting a 6% year-over-year increase. Though EPS of $0.04 fell slightly short of expectations, adjusted EBITDA of $98 million underscored strong operating leverage.
CEO Ben Kovler highlighted new store openings, including a RISE dispensary in Orlando, Florida, and the company’s first adult-use sales in Ohio as growth catalysts.
Kovler also commented on regulatory uncertainty, stating that federal cannabis reform remains frustratingly slow. However, consumer demand remains strong and the company is investing in brand development and operational efficiencies to drive future growth.
Read next: A Tale Of Two Trumps: Clemency For Some, Death For Others In His Drug Policy Approach
Lead image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.